Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats

Journal of Nutrition

Volumn 140, Issue 5, 2010, Pages 962-968

  Wojciechowski, Peter ^a   Juric, Danijel ^a   Louis, Xavier Lieben ^a   Thandapilly, Sijo Joseph ^a   Yu, Liping ^a   Taylor, Carla ^a   Netticadan, Thomas ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RESVERATROL;

ABDOMINAL AORTA; ARTICLE; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE; HEART VENTRICLE HYPERTROPHY; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; ANTIOXIDANTS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; HEART; LIPID PEROXIDATION; MALE; MYOCARDIUM; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; VENTRICULAR PRESSURE;

RATTUS;

EID: 77951435651     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.109.115006     Document Type: Article

References (30)

1. Latronico MV, Elia L, Condorelli G, Catalucci D. Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment. Int J Biochem Cell Biol. 2008;40:1643-1648
2. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature. 2008;451:919-928
3. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589
4. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45-79.
5. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006;367:356-367
6. Selvetella G, Hirsch E, Notte A, Tarone G, Lembo G. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res. 2004;63:373-380 (Pubitemid 38970181)
7. De Luca L, Mebazaa A, Filippatos G, Parissis JT, Bohm M, Voors AA, Nieminen M, Zannad F, Rhodes A, et al. Overview of emerging pharmacologic agents for acuteheart failure syndromes. Eur J Heart Fail. 2008;10:201-213
8. Tavares M, Rezlan E, Vostroknoutova I, Khouadja H, Mebazaa A. New pharmacologic therapies for acute heart failure. Crit Care Med. 2008;36:S112-20.
9. Tunuguntla A. Emerging drug therapies for the management of acute decompensated heart failure. Tenn Med. 2007;100:33-37
10. Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC. Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol. 2008;101:E89-103.
11. De Caterina R, Zampolli A, Del Turco S, Madonna R, Massaro M. Nutritional mechanisms that influence cardiovascular disease. Am J Clin Nutr. 2006;83:S421-6. (Pubitemid 44713212)
12. Kalra EK. Nutraceutical: definition and introduction. AAPS PharmSci. 2003;5:E25.
13. Ramaa CS, Shirode AR, Mundada AS, Kadam VJ. Nutraceuticals: an emerging era in the treatment and prevention of cardiovascular diseases. Curr Pharm Biotechnol. 2006;7:15-23. (Pubitemid 44110362)
14. Das S, Das DK. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 2007;2:133-138 (Pubitemid 46957321)
15. Juric D,Wojciechowski P, Das DK, Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol. 2007;292:H2138-43. (Pubitemid 47084592)
16. Cantor EJ, Babick AP, Vasanji Z, Dhalla NS, Netticadan T. A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overload. J Mol Cell Cardiol. 2005;38:777-786 (Pubitemid 40591742)
17. Sahn DJ, DeMaria A, Kisslo J,Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083 (Pubitemid 9091990)
18. Cipolla MJ, Smith J, Bishop N, Bullinger LV, Godfrey JA. Pregnancy reverses hypertensive remodeling of cerebral arteries. Hypertension. 2008;51:1052-1057 (Pubitemid 351398950)
19. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, Zhang CN, Liu G, Liu YQ, et al. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med. 2005;38:243-257 (Pubitemid 39656135)
20. Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE, Dyck JR. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem. 2008;283:24194-24201
21. Thandapilly SJ,Wojciechowski P, Behbahani J, Louis XL, Yu L, Juric D, Kopilas MA, Anderson HD, Netticadan T. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens. 2010;23:192-196
22. Kobayashi M, Machida N, Tanaka R, Yamane Y. Effects of beta-blocker on left ventricular remodeling in rats with volume overload cardiac failure. J Vet Med Sci. 2008;70:1231-1237
23. Tokioka-Akagi T, Fujimori A, Shibasaki M, Inagaki O, Yanagisawa I. Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload. Jpn J Pharmacol. 2001;86:79-85. (Pubitemid 32529748)
24. Gerdes AM, Clark LC, Capasso JM. Regression of cardiac hypertrophy after closing an aortocaval fistula in rats. Am J Physiol. 1995;268:H2345-51.
25. Shigematsu S, Ishida S, Hara M, Takahashi N, Yoshimatsu H, Sakata T, Korthuis RJ. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med. 2003;34:810-817 (Pubitemid 36316064)
26. Tatlidede E, Sehirli O, Velioglu-Ogunc A, Cetinel S, Yegen BC, Yarat A, Suleymanoglu S, Sener G. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res. 2009;43:195-205.
27. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart. 2007;93:903-907 (Pubitemid 47122034)
28. Buys ES, Raher MJ, Blake SL, Neilan TG, Graveline AR, Passeri JJ, Llano M, Perez-Sanz TM, Ichinose F, et al. Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload. Am J Physiol Heart Circ Physiol. 2007;293:H620-7.
29. Kiriazis H, Wang K, Xu Q, Gao XM, Ming Z, Su Y, Moore XL, Lambert G, Gibbs ME, et al. Knockout of beta(1)- and beta(2)- adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis. Br J Pharmacol. 2008;153:684-692
30. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation. 2002;105:236-243